Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis

Mitsuru Mizuno*, Nobutake Ozeki, Ichiro Sekiya

Center for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental University (TMDU), 1-5-45, Bunkyo-ku, Yushima, Tokyo 113-8519, Japan

A R T I C L E   I N F O

Article history:
Received 9 February 2022
Received in revised form 25 April 2022
Accepted 1 June 2022

Keywords:
Osteoarthritis
Cell therapy
Trisomy 7
Synovial mesenchymal stem cell
Karyotypic abnormality

A B S T R A C T

Cell therapy is a promising alternative treatment approach currently under study for osteoarthritis (OA), the most common chronic musculoskeletal disease. However, the mesenchymal stem cells (MSCs) used in cell therapy to treat OA are usually expanded in vitro to obtain sufficient numbers for transplantation, and their safety has not been fully assessed from multiple perspectives. Analysis of karyotypic abnormalities, in particular, is important to ensure the safety of cells; however, chromosomal mutations may also occur during the cell-expansion process. In addition, there have been many reports showing chromosome abnormalities, mainly trisomy 7, in the cartilage and synovium of patients with OA as well as in normal tissues. The suitability of cells with these karyotypic abnormalities as cells for cell therapy has not been evaluated. Recently, we assessed the safety of using cells with trisomy 7 from the osteoarthritic joint of a patient for transplantation, and we followed up with the patient for 5 years. This study showed analysis for copy number variant and whole-genome sequencing, compared with blood DNA from the same patient. We did not find any abnormalities in the genes regardless of trisomy 7. No side effects were observed for at least 5 years in the human clinical study. This suggests that the transplantation of cultured cells with trisomy 7 isolated from an osteoarthritic joint and transplanted into the osteoarthritic joints of the same person is not expected to cause serious adverse events. However, it is unclear what problems may arise in the case of allogeneic transplantation. Different types of risks will also exist depending on other transplantation routes, such as localization to the knee-joint only or circulation inflow and lung entrapment. In addition, since the cause of trisomy 7 occurrence remains unclear, it is necessary to clarify the mechanism of trisomy 7 in OA to perform cell therapy for OA patients in a safer manner.

© 2022, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The safety of cells for cell therapy needs to be assessed from multiple perspectives [1–3]. Analysis of karyotypic abnormalities, in particular, is important to ensure the safety of cells. Mesenchymal stem cells (MSCs) are widely used in clinical practice as a cell source for cell therapy [4–8]. MSCs are usually expanded in vitro to obtain sufficient numbers of cells for transplantation; however, chromosomal mutations may occur during the expansion process [9–11]. Moreover, there have been many reports showing the presence of chromosome abnormalities, mainly trisomy 7, in cartilage and synovial cells in patients with osteoarthritis (OA; Table 1). The developmental mechanism of trisomy 7 in OA patients is not clear; however, trisomy 7 is also found in patients with rheumatoid arthritis (RA) and in normal tissues. Therefore, the patient’s own cells may possess trisomy 7. The suitability of cells with these karyotypic abnormalities as cells for cell therapy has not been evaluated. Recently, we reported on safety issues related to transplantation [12]. In this review article, we focused on research studies reporting on the transplantation of cells with trisomy 7 and discussed the current situation for cell therapy in OA. We also review reports from the 1990s regarding cells with trisomy 7 in OA patients and on the use of cultured cells with chromosome abnormalities for cell therapy.

2. Osteoarthritis

OA is the most common chronic musculoskeletal disease, occurring in the knee, spine, hip, hand, foot, and shoulder, or among other joints. Arthritis is considered to be the fourth leading cause of disability worldwide [13–15]. Knee OA, the most common form of OA, is a complex disease involving joint components such as bone, cartilage, meniscus, and synovium. Recently, research studies on the pathology and the cellular and molecular biological processes underlying OA have increased; however, the complexity of this condition is still unclear.

When the failure of joint tissue occurs, early intervention through surgical procedures is the most effective therapeutic solution before it progresses to OA [16]. Unfortunately, when OA of a joint has fully developed and does not respond to conventional conservative therapy, joint replacement with an artificial joint is currently the accepted treatment. In the United States, an estimated 600,000 knee replacements are performed annually [17]. According to the National Database of Health Insurance Claims and Specific Health Checkups of Japan, ~150,000 cases of arthroplasty are reported, and 80,000 knee replacements are performed annually [18]. However, knee replacement surgery is not without potential serious complications [19,20]. As many as 20% of patients continue to have knee pain and other problems after joint replacement surgery [21]. The frequency of revision total arthroplasty within 10 years is 6.2–8.9% [22,23]. These problems have led to the development of alternative treatment methods.

Cell therapy is expected to be one of the alternative treatment methods for OA, and various technological developments are being attempted. Culturing of the cells used in this treatment requires considerable effort and cost because the cells need to be cultured in a clean-room environment [24]. Despite this, many clinical trials using cell therapy are currently being conducted. A search on clinicaltrials.gov using the keywords “cell therapy” and “knee osteoarthritis” in January, 2022, revealed 169 registered trials. The cells used in these studies include adipose-derived stem cells, bone marrow–derived MSCs, umbilical cord–derived MSCs, and synovium-derived MSCs [25–27].

3. Cell culture in cell therapy and chromosome abnormalities

Cell preparation for transplantation requires the isolation and culturing of cells from tissues to obtain sufficient cell numbers in vitro. Mass culturing to obtain a quantity of cells that can be transplanted may introduce risks. Studies using bone marrow–derived MSCs have shown chromosomal alterations after four passages [9]. Other studies revealed that karyotypic abnormalities were detected in 6 of 144 MSC samples (4%) [10]. In peripheral blood–derived MSC passing experiments, genomic instabilities, such as single-nucleotide variations, were detected from passage 1 to passage 9 [11]. In neural stem cells, chromosome abnormalities were detected in 9 of 97 samples (9%), suggesting that instability varies by cell type [10]. Therefore, when cells are cultured and used in large quantities, evaluation of the instability prior to using the cells is important.

4. Chromosome abnormalities in osteoarthritis

Chromosome abnormalities are known to be acquired in vivo as well as in cell culture. Chromosome abnormalities in OA have been reported in several instances since the 1990s (Table 1). F. Mertens et al. reported that in cultured cells of osteophytes, synovium, and cartilage from patients with knee OA, chromosome abnormalities were present in about 90% of the cases [28]. Chromosome abnormalities were observed in the osteophytes of 27 of 29 patients (93%), the synovia of 16 of 17 patients (94%), and the cartilage of 8 of 9 patients (89%). These chromosome abnormalities were not related to the grade of knee OA based on radiographic evaluation. Most of these abnormalities were trisomy 7, trisomy 5, and deletion of the Y chromosome, although inversions of chromosomes 1 and 22 and translocations between chromosomes 13 and 22 were also observed. In samples of 100–200 cells, trisomy 7 was found to be particularly frequent, observed in 6 ± 5% of osteophytes, 8 ± 6% of synovial cells, and 6 ± 6% of chondrocytes. In cells isolated from patients with anterior cruciate ligament tear or meniscus tear, trisomy 7 was found in 3 ± 2% (6 of 17) patients. These results suggested that these somatic abnormalities occur early in the development of knee OA and may be involved in the pathogenesis of the disease [28].

RW Kinne et al. analyzed enzyme-digested synovial tissue cells and cultured synovial cells isolated from patients with knee OA and RA using fluorescence in situ hybridization (FISH), and peripheral blood and skin cells as controls [29]. In cultured synovial cells isolated from OA patients, chromosome abnormalities were observed in all 16 patients. In cultured synovial cells isolated from...
RA patients, chromosome abnormalities were observed in all 10 patients. The most frequent chromosome abnormality, trisomy 7, was observed in 20 ± 14% of synovial cells isolated from OA patients and in 13 ± 11% of synovial cells isolated from RA patients, out of 10–50 cells examined. Chromosome abnormalities were also observed in enzyme-digested synovial-tissue cells before culture, including in all 13 patients with OA and in all 5 patients with RA, whereas peripheral-blood control samples showed no chromosome abnormalities. In RA patients, abnormalities found in chromosome 7, X, and Y. In this study, chromosome abnormalities were found in 33% (7 of 21) of the patients. Trisomy 7 was detected in 2 ± 1% of the 200 cells analyzed; deletions of chromosome X were found in 57% (12 of 21) of the patients and in 4 ± 2% of the 200 cells. They also reported the presence of chromosome abnormalities in OA of the lumbar spine at a frequency similar to that of the knee [30].

The variations in the ratios of trisomy 7 in these previous reports appear to be mainly due to the limitations of the analytical techniques, including the variability in the tissues and cells, and because the number of cells that can be analyzed by the G-band method and FISH is limited to about 200 cells [31]. While several studies have reported chromosome abnormalities occurring in osteoarthritic tissue, the frequency may increase or decrease depending on the detection sensitivity.

The array comparative genomic hybridization (CGH) method can detect chromosome aberrations based on comprehensive analysis, but it cannot detect structural aberrations such as inversions and translocations. Using array CGH, Stumm et al. found a deletion of the Y chromosome in 50% (4 of 8) of the OA patients analyzed [32]. In this analysis, the authors investigated the functional effects of chromosome abnormalities focusing on SRY-box transcription factor 9 (SOX9), a Y-chromosome gene involved in early chondrogenic differentiation. The incidence of deletion of chromosome Y in chondrocytes increased with age; however, the expression of COL2A1 and ACAN, which are related to the extra-cellular cartilage matrix, did not change. Therefore, the authors considered that the presence of chromosome abnormalities did not affect function in the cultured cells [32].

4.1. Trisomy 7 in osteoarthritis and other tissues

Trisomy 7, in particular, is frequently detected in cells derived from osteoarthritic joints (Table 1). It has also been found in other

Table 1

Previous reports on the detection ratio of trisomy 7 and other chromosomal abnormalities, mainly in arthritis.

| Primary disease | Analysis object | No. Of cases | Chromosome abnormality ratios in cases | Major abnormalities | Chromosome abnormality ratios in cells | References |
|-----------------|-----------------|--------------|--------------------------------------|---------------------|---------------------------------------|------------|
| PVNS            | Synovial cells  | 4            | 100%                                 | Trisomy 7           | 2–42.5%                               | [54]       |
| RA              | Synovial cells  | 7            | 86%                                  | Trisomy 5           | 0–32%                                 | [55]       |
| RA              | Synovial cells  | 5            | 100%                                 | Trisomy 7           | 0–80%                                 | [56]       |
| OA              | Osteophytes     | 29           | 93%                                  | Trisomy 7           | 0–29%                                 | [28]       |
| OA              | Synovial cells  | 17           | 94%                                  | Trisomy 5           | 0–50%                                 |            |
| OA              | Synovial cells  | 9            | 100%                                 | Trisomy 7           | 0–24%                                 | [57]       |
| OA              | Synovial cells  | 9            | N.A.                                 | Trisomy 7           | 5–20%                                 | [58]       |
| RA              | Synovial cells  | 8            |                                      | Trisomy 7           | 5–20%                                 |            |
| OA              | Synovial cells  | 5            |                                      | Trisomy 7           | 0.50%                                 | [29]       |
| OA              | Synovial tissue enzyme-digested cells | 13 | 100%                                 | Trisomy 7           | 5%                                    | [29]       |
| OA              | Synovial tissue enzyme-digested cells | 16 | 100%                                 | Monosomy X          | 5–10%                                 |            |
| RA              | Synovial tissue enzyme-digested cells | 5 | 100%                                 | Trisomy 7           | 15%                                    |            |
| OA              | Synovial cells  | 10           | 90%                                  | Trisomy 7           | 15%                                    |            |
| NA              | Synovial tissue enzyme-digested cells | 1–3 | 0%                                   | N.D.                 | N.D.                                  |            |
| OA              | Synovial cells  | 8            | 100%                                 | Trisomy 7           | 4–30%                                 | [59]       |
| PVNS            | Synovial cells  | 2            | 100%                                 | Trisomy 7           | 0%                                    |            |
| HS + CS         | Synovial cells  | 2            | 100%                                 | Trisomy 7           | 0%                                    |            |
| OA              | Synovial cells  | 2            | 100%                                 | Trisomy 7           | 0%                                    |            |
| OA              | Paraffin-embedded synovia | 8 | 100%                                 | Trisomy 7           | 2–12%                                 |            |
| PVNS            | Paraffin-embedded synovia | 2 | 100%                                 | Trisomy 7           | 3–15%                                 |            |
| HS + CS         | Paraffin-embedded synovia | 2 | 100%                                 | Trisomy 7           | 4–5%                                  |            |
| OA              | Paraffin-embedded synovia | 2 | 100%                                 | Trisomy 7           | 0–2%                                  |            |
| OA              | Synovial cells  | 9            | 11.1%                                | Trisomy 7           | 0–0.05%                               | [34]       |
| OA              | Synovial cells  | 10           | 50%                                  | Trisomy 7           | 0–39.5%                               |            |
| OA              | Synovial tissue enzyme-digested cells | 9 | 100%                                 | Trisomy 7           | 1–25%                                 | [33]       |
| OA              | Synovial cells  | 12           | 100%                                 | Trisomy 7           | 1–42%                                 |            |
| OA              | Synovial macrophages | 13 | 92%                                  | Trisomy 7           | 0–24%                                 |            |
| OA              | Synovial tissue enzyme-digested cells | 5 | 100%                                 | Trisomy 7           | 4–12%                                 |            |
| RA              | Synovial cells  | 6            | 100%                                 | Trisomy 7           | 5–46%                                 |            |
| OA              | Synovial macrophages | 8 | 100%                                 | Trisomy 7           | 2–9%                                  |            |
| JT              | Synovial tissue enzyme-digested cells | N.A. |                                      | N.A.                 | N.A.                                  |            |
| OA              | Synovial cells  | 3            | 60%                                  | Trisomy 7           | 0–5%                                  |            |
| OA              | Chondrocytes    | 3            | 66%                                  | Trisomy 7           | 6–74%                                 |            |
| OA              | Synovial tissue enzyme-digested cells | 44 | 18%                                  | Trisomy 7           | 4–12%                                 | [30]       |

Abbreviations: PVNS, pigmented villonodular synovitis; OA, osteoarthritis; RA, rheumatoid arthritis; NA, non-arthritis; HS, hemorrhagic synovitis; CS, chronic synovitis; JCA, juvenile chronic arthritis; JT, joint trauma; N.A., not assigned; N.D., not detected.
tissues, including in macrophages derived from bronchoalveolar lavage fluid in chronic obstructive pulmonary disease; therefore detection of trisomy 7 is considered to reflect an inflammatory response [33]. Trisomy 7 is also common in other tissues, such as the colon, kidneys, and skin, and its rate may increase with age [34–37]. There are other reports of trisomy 7 in cell cultures of normal kidney and brain tissue [38,39]. In colorectal cancer, trisomy 7 with aberrant expression of EGFR is frequently observed [40]. The correlation between chromosome 7 and OA was reported in a genome-wide association study of 1341 Dutch human cases of OA; 7q22 was detected as a novel common variant affecting the prevalence and progression of OA [41]. However, it is not clear whether chromosome 7 trisomy is a cause or a consequence of OA. Thus, the suitability of cells with trisomy 7 as cells for cell therapy needs to be further evaluated.

4.2. Trisomy 7 in cultured cells for cell therapy

Cells isolated from the synovium of OA patients also possess trisomy 7. Synovial MSCs are cells with colony-forming ability and differentiation capability isolated from the synovium and are widely used in clinical practice as a cell source for cell therapy [42–45]. However, the presence of trisomy 7 has been reported in cultured synovial MSCs (Fig. 1); these MSCs were transplanted into knee joints and followed up for 5 years [12]. Various investigations related to this study are ongoing using primary synovial MSCs and their surplus passaged cells. Cell culture growth curves were analyzed for up to 15 cell passages in the presence and absence of trisomy 7. As a safety test, synovial MSCs with trisomy 7 were subjected to the soft agar colony formation test, a transplantation test into immunodeficient mice, whole genome analysis, and DNA methylation analysis. For functional evaluation, gene expression profiles, cell surface antigens, and chondrogenic potential were analyzed. In 3 of the 10 patients, the transplanted synovial MSCs had trisomy 7 in 5–10% of the cells. In the growth-curve analysis, no difference was observed between synovial MSCs with and without trisomy 7. The effect of synovial MSC from passage 0 to passage 15 on the proportions of trisomy 7 was variable and showed three patterns: invariant, increasing, and decreasing. Synovial MSCs are a heterogenous cell population and form diverse colonies, which may explain the various patterns of trisomy 7 [46,47]. There were no differences in the expression of tumor-related genes, such as CDKN1A, CDKN2A, MYC, and KIT; or genes on chromosome 7, such as EGFR, HGF, IL6, and PPIA, depending on the presence or absence of trisomy 7. In a transplantation study into immunodeficient mice, HT-1080 cells formed tumors, whereas synovial MSCs with trisomy 7 did not form tumors [12]. Whole genome sequence analysis and DNA methylation analysis showed no difference in the results between synovial MSCs with and without trisomy 7. No gene abnormalities were observed, regardless of trisomy 7. There were also no differences in cell-surface antigens or chondrogenic potential between synovial MSCs with and without trisomy 7. None of the 10 patients, with or without trisomy 7, exhibited any tumor formation by 5 years after transplantation. These results support the conclusion that the presence of trisomy 7 in autologous synovial MSCs does not affect subsequent transplantation safety and functional analysis, and trisomy 7 does not cause tumor formation for 5 years after transplantation.

The presence of trisomy 7 in chondrocytes derived from OA patients was described in a June 5, 2012, report reviewing J-TEC autologous cultured cartilage (JACC), a cell therapy and gene therapy product approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan [48]. JACC is a three-dimensionalized culture of chondrocytes in collagen gel. In an evaluation using chondrocytes isolated from the knee-joint cartilage of three patients with OA, chromosome abnormalities were observed in all pre-cultured cells, and trisomy 7 was detected in 2 out of 20 cells in all cases. In one case, trisomy 7 was detected at the same rate before

Fig. 1. Trisomy 7 observed in synovial mesenchymal stem cells in a clinical trial. Chromosome X or Y are not shown to prevent patient identification.
and after culture. Normal chromosomes were observed in the other two cases after culture. Since there were no new chromosome aberrations after culture, the report (June 5th, 2012) described that chondrocyte cytogenetic stability was not affected by the culture process using the stated manufacturing method for this product. Five years after manufacturing and marketing approval of JACC by the PMDA, no adverse events suspected to be related to karyotypic abnormalities were reported in post-marketing surveillance [49].

Yokoyama et al. evaluated chondrocytes with trisomy 7 derived from patients with knee OA and the effect of passing as well as tumorigenicity following transplantation. The karyotype of chondrocytes cultured for a longer time period than the normal process showed no abnormal alterations based on array-CGH and G-band results. The authors transplanted cultured chondrocyte sheets into immunodeficient mice, and subsequent testing revealed no tumorigenicity associated with the chondrocyte sheets with trisomy 7. The authors confirmed by bioluminescence imaging that the transplanted chondrocyte sheets remained in the knee joint and did not transfer elsewhere for one month [50].

5. Allogeneic transplantation and route of administration

Based on these previous reports, the transplantation of cultured cells isolated from an osteoarthritic joint into one’s own osteoarthritic joints is not expected to cause serious adverse events. However, it is unclear what problems may arise in the case of allogeneic transplantation. Different types of risks will exist depending on the route of transplantation, even for the same cultured cells. Therefore, each treatment target requires a unique risk-management strategy. For example, synovial MSCs implanted in the joint will remain in the joint and have no effect on the whole body [51,52]. However, intravenously administered MSCs can adhere to various tissues—such as the lungs—and be maintained for long periods of time, which may pose as-yet-unknown risks in the future [53]. Even though no side effects have been observed in transplantsations using cells with chromosome abnormalities in previous reports, this does not guarantee that allogenic cells with chromosome abnormalities can be safely transplanted into humans without considering the type of cultured cells or the method of administration.

6. Conclusions

The safety of cells with karyotypic abnormalities generated during culture has not yet been evaluated. Therefore, the occurrences of karyotypic abnormalities in vivo, by disease, and in vitro, by culture, need to be considered separately. Clarifying the mechanism of trisomy 7 in patients with OA will also help in providing safe cell therapy for these patients.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank Kimiko Takanashi for the management of our laboratory. We would also like to thank Wiley Editing Services for English language editing. This research was funded by the Japan Agency for Medical Research and Development, grant number JP22bk0104148 to IS.

References

[1] Hayakawa T, Aoi T, Umewaza A, Ozawa K, Sato Y, Sawa Y, et al. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells. Regenerative Therapy 2015;2:70–80.
[2] Hayakawa T, Aoi T, Umewaza A, Ozawa K, Sato Y, Sawa Y, et al. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. Regenerative Therapy 2015;2:57–69.
[3] Hayakawa T, Aoi T, Umewaza A, Ozawa K, Sato Y, Sawa Y, et al. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells. Regenerative Therapy 2015;2:109–22.
[4] Hoch AI, Leach JR. Concise review: optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications. STEM CELLS Translational Medicine 2014;3:643–52.
[5] Mastrolia I, Foppiani EM, Murgia A, Candini O, Samarelli AV, Grisendi G, et al. Challenges in clinical development of mesenchymal stromal/stem cells: concise review. STEM CELLS Translational Medicine 2015;4:1135–48.
[6] Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues. STEM CELLS Translational Medicine 2012;1:51–6.
[7] Saito H, Radwitz L, Gilbert F, Nishi U, Tuan RS. Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. STEM CELLS Translational Medicine 2012;1:237–47.
[8] Tan AR, Hung CT. Concise review: mesenchymal stem cells for functional cartilage tissue engineering: taking cues from chondrocyte-based constructs. STEM CELLS Translational Medicine 2017;6:1295–303.
[9] Blasco R, de Souza Fernandes T, Lazzaroni-Silva L, Lecher B, Mencalha A, Pizzatti I, et al. Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Proefl 2013;46:10–22.
[10] Ben-David U, Mayshar Y, Benvenisty N. Large-scale Analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 2011;9:97–102.
[11] Kim M, Rhee J-K, Choi H, Kwon A, Kim J, Lee GD, et al. Passage-dependent accumulation of somatic mutations in mesenchymal stromal cells during in vitro culture revealed by whole genome sequencing. Sci Rep 2017;7.
[12] Mizuno M, Endo K, Katano H, Amano N, Nomura M, Hasegawa Y, et al. Transplantation of human autologous synovial mesenchymal stem cells with trisomy 7 into the knee joint and 5 years of follow-up. STEM CELLS Translational Medicine 2021;10(11):1530–40. https://doi.org/10.1002/scit.20-0491.
[13] Salmon JH, Rat AC, Sellam J, Michel M, Eschard JP, Guillemin F, et al. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthritis Cartilage 2016;24:1500–8.
[14] Xing D, Xu Y, Liu Q, Ke Y, Wang B, Li Z, et al. Osteoarthritis and all-cause mortality in worldwide populations: grading the evidence from a meta-analysis. Sci Rep 2016;6.
[15] Di Nicola V. Degenerative osteoarthritis a reversible chronic disease. Regenerative Therapy 2020;15:149–60.
[16] Ozeki N, Seil R, Krych AJ, Koga H. Surgical treatment of complex meniscus tear and disease: state of the art. Journal of ISAKOS: Joint Disorders & Orthopaedic Sports Medicine 2020;9(1):35–45. https://doi.org/10.1136/jisakos-2019-000380.
[17] Cramer P, Lu X, Kates SL, Singh JA, Li Y, Wolf BR. Total knee arthroplasty volume, utilization, and outcomes among medicare beneficiaries, 1991–2010. JAMA 2012;308.
[18] Katano H, Ozeki N, Kohno Y, Nakagawa Y, Koga H, Watanabe T, et al. Trends in arthroplasty in Japan by a complete survey, 2014–2017. J Orthop Sci 2020;23(4):676–81.
[19] Singh JA, Kudraukulam J, Riddle DL, Strand V, Tugwell P. Early postoperative mortality following joint arthroplasty: a systematic review. J Rheumatol 2011;38:1507–13.
[20] Wyld V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain 2011;152:566–72.
[21] Bourne RB, Chessworth BM, Davis AM, Mahomed NN, Charron KD. Patient satisfaction after total knee arthroplasty: who is satisfied and who is not? Clin Orthop Relat Res 2010;468:57–63.
[22] Dy CJ, Marx RG, Bozic KJ, Pan TJ, Padgett DE, Lyman S. Risk factors for revision within 10 Years of total knee arthroplasty. Clin Orthop Relat Res 2014;472:1198–207.
[23] Pabinger C, Bergfeld A, Boehler N, Labek G. Revision rates after knee replacement. Cumulative results from worldwide clinical studies versus joint registers. Osteoarthritis Cartilage 2013;21:203–8.
[24] Mizuno M, Endo K, Katano H, Tsuji A, Kojima N, Watanabe K, et al. The environmental risk assessment of cell-processing facilities for cell therapy in a Japanese academic institution. PLoS One 2020;15.
[25] Anderson JA, Little D, Toth AP, Moorman CT, Tucker BS, Ciccotti MG, et al. Stem cell therapies for knee cartilage repair. Am J Sports Med 2013;42:2253–61.
[26] Freitag J, Bates D, Boyd R, Shah K, Barnard A, Huguenin L, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy – a review. BMC Musculoskelet Disord 2016;17.

[27] Gupta PK, Das AK, Chullikana A, Majumdar AS. Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Cell Res Ther 2012;3.

[28] Mertens F, Palisson E, Lindstrand A, Toksvig-Larsen S, Knutula S, Larramendy ML, et al. Evidence of somatic mutations in osteoarthritis. Hum Genet 1996;98:651–6.

[29] Kinne RW, Liehr T, Beensien V, Kunisch E, Zimmermann T, Holland H, et al. Mosaic chromosomal aberrations in synovial fibroblasts of patients with rheumatoid arthritis, osteoarthritis, and other inflammatory joint diseases. Arthritis Res 2001;3:319–30.

[30] Castellanos MV, Hernández JM, Ramos L, Belén González M, Gutiérrez NC, Leone PE, et al. Chromosomal abnormalities are related to location and grade of osteoarthritis. Osteoarthritis Cartilage 2004;12:982–5.

[31] Justino Ferreira R, Carolina Irídio A, Correa Cunha R, Cesar Francisco J, Cesar Guartia-Souza L, Venkata Naga Srikant C, et al. Controversies about the chromosomal stability of cultivated mesenchymal stem cells: their clinical use is it safe? Curr Stem Cell Res Ther 2012;7:356–63.

[32] Stumm M, Roger E, Gaissmaier CG, Olwaid C, Blankenburg M, Wegner RD, et al. Genomic chondrocyte culture profiling by array-CGH, interphase-FISH and RT-PCR. Osteoarthritis Cartilage 2012;20:1039–45.

[33] Kinne RW, Kunisch E, Beensien V, Zimmermann T, Emmrich F, Petrov P, et al. Synovial fibroblasts and synovial macrophages from patients with rheumatoid arthritis and other inflammatory joint diseases show chromosomal aberrations. Gene Chromosome Cancer 2003;38:53–67.

[34] Broberg K, Toksvig-Larsen S, Lindstrand A, Mertens F. Trisomy 7 accumulates with age in solid tumors and non-neoplastic synovia. Genes Chromosomes Cancer 2001;30:310–5.

[35] Fisher R, Gibas Z, Sandberg AA. Involvement of chromosomes 7 and 12 in large bowel cancer: trisomy 7 and 12q. Cancer Genet Cytogenet 1983;9:329.

[36] Becher R, Gibas Z, Sandberg AA. Involvement of chromosomes 7 and sex chromosome loss in human brain tissue. Cytogenet Genome Res 1990;53:123

[37] Johansson B, Heim S, Mandahl N, Mertens F, Mitelman F. Trisomy 7 in non-neoplastic cells. Gene Chromosome Cancer 1993;6:199–205.

[38] Heim S, Mandalh N, Jin Y, Stromblad S, Lindstrom E, Sallford LG, et al. Trisomy 7 and sex chromosome loss in human brain tissue. Cytogenet Genome Res 1989;52:136–8.

[39] Elving P, Cigudosa JC, Lundgren R, Limon J, Mandalh N, Kristoffersson U, et al. Trisomy 7, trisomy 10, and loss of the Y chromosome in short-term cultures of normal kidney tissue. Cytogenet Genome Res 1990;53:123–5.

[40] Ly P, Kim SB, Kaisani AA, Marian G, Wright WE, Shay JW. Aneuploid human colon epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation. Oncogene 2012;32:3139–46.

[41] Kerkhof HJM, Lories RJ, Meulenbelt I, Jonsdottir I, Valdes AM, Arp P, et al. A genome-wide association study identifies a locus on chromosome 7q22 to influence susceptibility for osteoarthritis. Arthritis Rheum 2010;62(2):499–510.

[42] Sekiya I, Koga H, Otake K, Nakagawa Y, Kato H, Ozeki N, et al. Additional use of synovial mesenchymal stem cell transplantation following surgical repair of a complex degenerative tear of the medial meniscus of the knee: a case report. Cell Transplant 2019;28:1445–54.

[43] Sekiya I, Muneta T, Horie M, Koga H. Arthroscopic transplantation of synovial stem cells improves clinical outcomes in knees with cartilage defects. Clin Orthop Relat Res 2015;473:2316–26.

[44] Sekiya I, Koga H, Katano H, Mizuno M, Kohno Y, Otake K, et al. Second-look arthroscopy after meniscus repair and synovial mesenchymal stem cell transplantation to treat degenerative flaps and radial tears of the medial meniscus: a case report. J Orthop Sci 2021;In Press.

[45] Sekiya I, Katano H, Mizuno M, Koga H, Masumoto J, Tomita M, et al. Alterations in cartilage quantification before and after injections of mesenchymal stem cells into osteoarthritic knees. Sci Rep 2021;11.

[46] Mizuno M, Katano H, Shimozaki Y, Sanami S, Ozeki N, Koga H, et al. Time-lapse image analysis for whole colony growth curves and daily distribution of the cell number per colony during the expansion of mesenchymal stem cells. Sci Rep 2019;9.

[47] Mizuno M, Katano H, Mabuchi Y, Ogata Y, Ichinose S, Fuji S, et al. Specific markers and properties of synovial mesenchymal stem cells in the surface, stromal, and perivascular regions. Stem Cell Res Ther 2018;9:123.

[48] Kato Y, Chavez J, Yanada S, Hattori S, Takazawa S, Ohuchi H. A large knee osteochondral lesion treated using a combination of osteochondral autograft transfer and second-generation autologous chondrocyte implantation: a case report. Regenerative Therapy 2019;10:10–6.

[49] Sugimoto A. The post marketing surveillance covering all patients who received autologous cultured chondrocyte (JACC), Past and Present (in Japanese). Bone Joint Nerve 2018;8:403–8.

[50] Yokoyama M, Sato M, Umezawa A, Mitani G, Takagaki T, Yokoyama M, et al. Assessment of the safety of chondrocyte sheet implantation for cartilage regeneration. Tissue Eng C Methods 2016;22:59–68.

[51] Koga H, Muneta T, Nagase T, Nimura A, Ju Y-J, Mochizuki T, et al. Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit. Cell Tissue Res 2008;333:207–15.

[52] Ozeki N, Muneta T, Koga H, Nakagawa Y, Mizuno M, Tsuji K, et al. Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats. Osteoarthritis Cartilage 2016;24:1061–70.

[53] Schrepler S, Deuse T, Reichengurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc 2007;39:573–6.

[54] Fletcher JA, Henkle C, Atkins L, Rosenberg AE, Morton CC. Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: confirmation of trisomy 7 in uncultured cells. Gene Chromosome Cancer 1992;4:264–6.

[55] Ermiş A, Hopf T, Hanselmann R, Remberger K, Welter C, Dooley S, et al. Clonal chromosome aberrations in cell cultures of synovial tissue from patients with rheumatoid arthritis. Genes Chromosomes Cancer 1993;6:232–4.

[56] Ermiş A, Henn W, Remberger K, Hopf C, Hopf T, Zang KD. Proliferation enhancement by spontaneous multiclonality of chromosome 7 in rheumatic synovial cells in vitro. Hum Genet 1995;96:651–4.

[57] Broberg K, Limon J, Palisson E, Lindstrand A, Toksvig-Larsen S, Mandalh N, et al. Clonal chromosome aberrations are present in vivo in synovia and osteophytes from patients with osteoarthritis. Hum Genet 1997;101:295–8.

[58] Weiss KR, Georgescu HI, Gollin SM, Kang R, Evans CH. Trisomy 7 in synovial fibroblasts obtained from arthritic joints. Inflamm Res 1999;48(Suppl 2):S132–3.

[59] Dahlem A, Broberg K, Domanski HA, Toksvig-Larsen S, Lindstrand A, Mandalh N, et al. Analysis of the distribution and frequency of trisomy 7 in vivo in synovia from patients with osteoarthritis and pigmented villonodular synovitis. Cancer Genet Cytogenet 2001;131:19–24.